Nicholson most recently served as chief executive officer of Nimbus Therapeutics.
Prior to Nimbus, Nicholson spent 25 years at Merck, where he held various strategic, leadership and operational roles across diverse therapeutic areas including inflammation, immunology and neuroscience, amongst others.
Nicholson began his career at Merck Frosst in Montreal as a senior research biologist and advanced through various positions of increasing responsibility, including vice president and site head of the Merck Neurosciences Research site in San Diego, vice president of immunology and infectious diseases and then vice president and worldwide discovery head for the Bone, Respiratory, Immunology and Endocrine franchise based in New Jersey.
Nicholson has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally recognized for his contributions to the field of apoptotic cell death.
He is the recipient of multiple academic and professional honors. Don is also a member of the board of directors of Kymera Therapeutics and Generation Bio.
Jnana Therapeutics is a biotechnology company creating the first drug discovery platform to unlock the solute carrier family of metabolite transporters as a therapeutic target class.
Jnana is systematically targeting SLCs, the cell's metabolite gates, to advance first-in-class therapies for diseases where patients have limited or no treatment options.
Headquartered in Boston, Jnana launched in 2017 with USD 50m in series A financing from investors including Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R and D Innovate.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins